Document is current
Any future updates will be listed below
-
Authors
Schiestl, Martin https://orcid.org/0000-0001-5784-9951
Roy, Nivedita
Trieb, Michael
Park, Joseph P.
Guillen, Elena
Woollett, Gillian https://orcid.org/0000-0002-9336-2769
Wolff-Holz, Elena https://orcid.org/0000-0002-8129-7381
- License Information
-
More Information
Article History
Accepted: 6 July 2025
First Online: 17 July 2025
Declarations
:
: No funding was received for this review.
: The authors, with the exception of Elena Guillen, are employed by companies developing and/or marketing biosimilar medicines. Gillian Woollett is an Editorial Board member of BioDrugs . Gillian Woollett was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Elena Wolff-Holz is an Editorial Board member of BioDrugs . Elena Wolff-Holz was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MS had the idea for the article. All authors contributed to the drafting, data analysis, review, and final approval of the manuscript.
